Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-12

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

NCT02157324

Chronic Lymphocytic Leukemia

ACTIVE_NOT_RECRUITING PHASE1

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611

Chronic Lymphocytic Leukemia

ACTIVE_NOT_RECRUITING PHASE2

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

NCT02296918

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Prolymphocytic Leukemia

COMPLETED PHASE1

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

NCT04178798

Chronic Lymphocytic Leukemia- Binet Staging System

COMPLETED PHASE3

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

NCT04008706

Chronic Lymphocytic Leukemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have relapsed/refractory disease or treatment naive deletion 17p.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.

Group Type EXPERIMENTAL

Acalabrutinib (Arm A)

Intervention Type DRUG

* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;
* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.
* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;
* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Acalabrutinib (Arm B)

Intervention Type DRUG

B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;

• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.

Arm B

Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.

Group Type EXPERIMENTAL

Acalabrutinib (Arm A)

Intervention Type DRUG

* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;
* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.
* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;
* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Acalabrutinib (Arm B)

Intervention Type DRUG

B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;

• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acalabrutinib (Arm A)

* A1a) acalabrutinib, dose A daily: biopsy (T) schedule W;
* A1b) acalabrutinib, dose A daily: biopsy (T) schedule V.
* A2a) acalabrutinib, dose B q 12 hours: biopsy (T) schedule Y;
* A2b) acalabrutinib, dose B q 12 hours; biopsy (T) schedule Z

Intervention Type DRUG

Acalabrutinib (Arm B)

B1c) acalabrutinib, dose A daily: biopsy (U) schedule W;

• B2c) acalabrutinib, dose B q12 hours: biopsy (U)) schedule Y.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ACP-196 ACP-196

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women 18 years of age and older with histologically confirmed disease.
* Active disease as defined by at least one of the following (IWCLL consensus criteria):

* Weight loss ≥10% within the previous 6 months
* Extreme fatigue
* Fevers of greater than 100.5ºF for ≥2 weeks without evidence of infection
* Night sweats for more than one month without evidence of infection
* Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
* Massive or progressive splenomegaly
* Massive nodes or clusters or progressive lymphadenopathy
* Progressive lymphocytosis with an increase of \>50% over a 2 month period, or an anticipated doubling time of less than 6 months
* Compensated autoimmune hemolysis
* Relapsed/Refractory CLL or treatment naïve CLL patients with 17p deletion, TP53 mutation, or NOTCH1 mutation
* Agreement to use acceptable methods of contraception during the study and for 30 days after the last dose of study drug if sexually active and able to bear or beget children.
* Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty and serial biopsies.
* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Exclusion Criteria

* Radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or investigational products in the last 4 weeks.
* Richter's transformation. Autoimmune hemolytic anemia or thrombocytopenia requiring steroid therapy. Impaired hepatic function

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No